JANX
Income statement / Annual
Last year (2024), Janux Therapeutics, Inc.'s total revenue was $10.59 M,
an increase of 30.99% from the previous year.
In 2024, Janux Therapeutics, Inc.'s net income was -$68.99 M.
See Janux Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$10.59 M |
$8.08 M |
$8.61 M |
$3.64 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$1.96 M
|
$841,000.00
|
$113,000.00
|
$13,000.00
|
$6,000.00
|
| Gross Profit |
$10.59 M
|
$6.13 M
|
$7.77 M
|
$3.52 M
|
-$13,000.00
|
-$6,000.00
|
| Gross Profit Ratio |
1
|
0.76
|
0.9
|
0.97
|
0
|
0
|
| Research and Development Expenses |
$68.39 M
|
$54.92 M
|
$53.44 M
|
$26.24 M
|
$3.04 M
|
$3.00 M
|
| General & Administrative Expenses |
$41.05 M
|
$26.14 M
|
$22.26 M
|
$10.33 M
|
$1.80 M
|
$772,000.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$41.05 M
|
$26.14 M
|
$22.26 M
|
$10.33 M
|
$1.80 M
|
$772,000.00
|
| Other Expenses |
$0.00
|
$0.00
|
$4.03 M
|
$257,000.00
|
-$1.74 M
|
$0.00
|
| Operating Expenses |
$109.44 M
|
$81.06 M
|
$75.70 M
|
$36.57 M
|
$4.84 M
|
$3.77 M
|
| Cost And Expenses |
$109.44 M
|
$81.06 M
|
$75.70 M
|
$36.57 M
|
$4.84 M
|
$3.77 M
|
| Interest Income |
$29.85 M
|
$14.69 M
|
$4.03 M
|
$257,000.00
|
$206,000.00
|
$233,000.00
|
| Interest Expense |
$0.00
|
$0.00
|
$4.03 M
|
$0.00
|
$206,000.00
|
$233,000.00
|
| Depreciation & Amortization |
$0.00
|
$1.96 M
|
$841,000.00
|
$113,000.00
|
$13,000.00
|
$6,000.00
|
| EBITDA |
-$98.85 M |
-$71.02 M |
-$66.25 M |
-$32.82 M |
-$4.83 M |
-$3.77 M |
| EBITDA Ratio |
-9.34
|
-8.79
|
-7.79
|
-9.05
|
0
|
0
|
| Operating Income Ratio |
-9.34
|
-9.03
|
-7.79
|
-9.05
|
0
|
0
|
| Total Other Income/Expenses Net |
$29.85 M
|
$14.69 M
|
$4.03 M
|
$257,000.00
|
-$1.94 M
|
-$233,000.00
|
| Income Before Tax |
-$68.99 M
|
-$58.29 M
|
-$63.06 M
|
-$32.67 M
|
-$6.78 M
|
-$4.00 M
|
| Income Before Tax Ratio |
-6.52
|
-7.21
|
-7.32
|
-8.98
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$8.91 M
|
-$113,000.00
|
-$1.53 M
|
$233,000.00
|
| Net Income |
-$68.99 M
|
-$58.29 M
|
-$54.15 M
|
-$32.56 M
|
-$5.26 M
|
-$4.24 M
|
| Net Income Ratio |
-6.52
|
-7.21
|
-6.29
|
-8.95
|
0
|
0
|
| EPS |
-1.28 |
-1.32 |
-1.31 |
-0.79 |
-0.13 |
-0.1 |
| EPS Diluted |
-1.28 |
-1.32 |
-1.31 |
-0.79 |
-0.13 |
-0.1 |
| Weighted Average Shares Out |
$53.75 M
|
$44.02 M
|
$41.47 M
|
$41.24 M
|
$41.61 M
|
$41.61 M
|
| Weighted Average Shares Out Diluted |
$53.75 M
|
$44.02 M
|
$41.47 M
|
$41.24 M
|
$41.61 M
|
$41.61 M
|
| Link |
|
|
|
|
|
|
